Glucocerebrosidase (GBA) is a lysosomal enzyme encoded by the GBA gene that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide [1]. GBA is essential for glycolipid metabolism, and pathogenic mutations in GBA cause Gaucher disease [2]. Importantly, GBA mutations represent the most significant genetic risk factor for Parkinson's disease (PD), with carriers having 5-10x increased risk [3].
Beyond its enzymatic function, GBA plays crucial roles in autophagy, alpha-synuclein metabolism, and lysosomal homeostasis [4]. The bidirectional relationship between GBA and alpha-synuclein represents a key pathogenic mechanism in PD and related synucleinopathies [5].
GBA is a 497-amino acid enzyme:
GBA catalyzes the hydrolysis of glucosylceramide (GlcCer) in the lysosome [10]:
GBA influences autophagy through multiple mechanisms [15]:
The GBA-alpha-synuclein relationship is bidirectional and pathogenic [19]:
GBA mutations are the most important genetic risk factor for PD [23]:
Multiple mechanisms connect GBA to PD pathogenesis [28]:
GBA-PD has distinct clinical features [33]:
Gaucher disease is caused by GBA deficiency [38]:
Multiple approaches target the GBA-alpha-synuclein axis [45]:
Ambroxol is being investigated for PD treatment [50]:
Brumshtein et al. GBA structure (2006). Nat Chem Biol. 2006. ↩︎
Grabowski, GBA and Gaucher disease (2008). Gastroenterology. 2008. ↩︎
Sidransky et al. GBA mutations in PD (2009). N Engl J Med. 2009. ↩︎
Mazzulli et al. GBA and alpha-synuclein (2011). Cell. 2011. ↩︎
Bae et al. GBA-alpha-synuclein relationship (2014). Nat Rev Neurol. 2014. ↩︎
Jonsson et al. GBA signal peptide (1987). J Biol Chem. 1987. ↩︎
Dvir et al. GBA catalytic mechanism (2003). EMBO Rep. 2003. ↩︎
Bergmann & Grabowski, GBA glycosylation (1989). J Biol Chem. 1989. ↩︎
Terlecky et al. GBA substrate binding (1995). J Biol Chem. 1995. ↩︎
Futerman & Zimran, GBA biochemistry (2006). Editor: Futerman AH. 2006. ↩︎
Lehman et al. GBA enzymatic activity (1969). Biochem J. 1969. ↩︎
Aerts et al. GBA pH optimum (1986). Biochim Biophys Acta. 1986. ↩︎
Grabowski et al. GBA catalysis (1990). Pediatr Res. 1990. ↩︎
Beutler & Grabowski, Gaucher disease (2001). The Metabolic and Molecular Bases of Inherited Disease. 2001. ↩︎
Schondorf et al. GBA and autophagy (2014). Nat Neurosci. 2014. ↩︎
Van der Vliet et al. GBA lysosomal function (2008). J Cell Sci. 2008. ↩︎
Mazzulli et al. GBA deficiency alpha-synuclein (2016). Cell. 2016. ↩︎
Gerez et al. GBA mitophagy (2020). Mol Neurobiol. 2020. ↩︎
Vincow et al. GBA alpha-synuclein cycle (2019). Proc Natl Acad Sci U S A. 2019. ↩︎
Cleeter et al. GBA activity alpha-synuclein (2013). J Biol Chem. 2013. ↩︎
Yap et al. Alpha-synuclein inhibits GBA (2021). Nat Commun. 2021. ↩︎
Kim et al. GBA-alpha-synuclein loop (2018). Mol Neurodegener. 2018. ↩︎
Anheim et al. GBA epidemiology (2012). Lancet Neurol. 2012. ↩︎
Lesage et al. GBA carrier frequency (2015). Brain. 2015. ↩︎
Siebert et al. GBA PD risk (2014). Parkinsonism Relat Disord. 2014. ↩︎
Nishioka et al. GBA PD age of onset (2011). Mov Disord. 2011. ↩︎
Winder-Rhodes et al. GBA PD cognitive (2013). Brain. 2013. ↩︎
Bae & Krainc, GBA pathogenic mechanisms (2015). Nat Rev Neurol. 2015. ↩︎
Kinghorn et al. GBA lysosomal dysfunction (2016). J Neurosci. 2016. ↩︎
Gomez et al. GBA mitochondria (2019). Mol Cell Biol. 2019. ↩︎
Hallett et al. GBA microglia (2022). Nat Neurosci. 2022. ↩︎
Maor et al. GBA ER stress (2016). Mol Cell Biol. 2016. ↩︎
McNeill et al. GBA-PD phenotype (2014). Mov Disord. 2014. ↩︎
Nekrutenko et al. GBA-PD motor symptoms (2015). Parkinsonism Relat Disord. 2015. ↩︎
Alcalay et al. GBA cognitive decline (2014). JAMA Neurol. 2014. ↩︎
Kuo et al. GBA autonomic dysfunction (2016). Mov Disord. 2016. ↩︎
Jankovic et al. GBA psychiatric features (2015). Neurology. 2015. ↩︎
Stirnemann et al. Gaucher disease (2017). J Clin Med. 2017. ↩︎
Charrow et al. Type 1 Gaucher (2000). Arch Intern Med. 2000. ↩︎
Prows et al. Type 2 Gaucher (1997). Pediatr Neurol. 1997. ↩︎
Davies et al. Type 3 Gaucher (2019). Blood Cells Mol Dis. 2019. ↩︎
Weinreb et al. GBA ERT (2002). Am J Hematol. 2002. ↩︎
Gomez & Ballard, GBA SRT (2015). Expert Opin Pharmacother. 2015. ↩︎
Ambinder & Roncarolo, Ambroxol chaperone (2021). Nat Rev Drug Discov. 2021. ↩︎
Sardi et al. GBA therapeutic strategies (2017). Neurotherapeutics. 2017. ↩︎
Patel et al. GBA activators (2018). Nat Chem Biol. 2018. ↩︎
Alfaro et al. GBA chaperones (2019). Mol Genet Metab. 2019. ↩︎
Xilouri et al. Autophagy enhancers alpha-synuclein (2016). Brain. 2016. ↩︎
Kalia & Lang, GBA combination therapy (2015). Lancet Neurol. 2015. ↩︎
Lavy et al. Ambroxol PD trial (2020). J Parkinsons Dis. 2020. ↩︎
Ambrosi et al. Ambroxol mechanism (2015). Mol Pharm. 2015. ↩︎
Silva et al. Ambroxol clinical trial (2021). Mov Disord. 2021. ↩︎
Foge et al. Ambroxol alpha-synuclein (2022). Neuropharmacology. 2022. ↩︎